Kornimate/medical-research-clean huggingface dataset:
the learning and memory of the experience of pain

Conditions: Pain

Summary: this study investigates the learning and memory of pain.


Eligibility criteria:
inclusion criteria: 1. male and female healthy volunteers. 2. 18-65 years of age. 3. right-handed. 4. fluency in english. ability to read and understand english; english can be a second language provided that the participant feels that he/she is able to understand all the questions used in the assessment measures. exclusion criteria: 1. any previous experience with conditioned analgesia/hyperalgesia paradigms. 2. presence of any illness or medication use that is judged to interfere with the trial. for example: psychiatric disorder according to the dsm-iv manual, medication that can influence cognition or emotional processing, i.e. sleep medication, antidepressants, anti-convulsants or opioids. 3. unwillingness to receive brief pain stimulation administered by a heat probe on the hand. 4. instability of responses to experimental heat pain 5. any contraindications to fmri scanning for subjects in experiment 2 (including metal implants, claustrophobia, history of head trauma, and pregnancy). 6. peripheral neuropathy.
a pilot study to evaluate ultrasonic surgical aspiration as a treatment modality for cervical dysplasia

Conditions: Cervical Dysplasia

Summary: ultrasonic surgical aspiration of the cervix may be an effective method of treating cervical dysplasia without compromising the integrity of the cervix in reproductive age women.

women age 18 to 55 years of age with cervical intraepithelial neoplasia 2 or 3 on colposcopy with a negative endocervical curettage are enrolled in a pilot study comparing ultrasonic surgical aspiration and traditional cervical excision procedure for the treatment of cervical dysplasia. in this pilot study, the patients serve as their own control group. prior to receiving the traditional treatment for cervical dysplasia consisting of cold knife conization with endocervical curettage, each patient's cervix is treated with ultrasonic surgical aspiration. the aspirate is sent to pathology and the results compared with the findings from the cervical cone biopsy. the patients then are followed with liquid-based cytology pap smears every 4 to 6 months until completion of the study enrollment/treatment period.

Eligibility criteria:
inclusion criteria: * cervical intraepithelial neoplasia ii or iii * negative endocervical curettage * not pregnant * cervical conization is part of treatment plan exclusion criteria: * positive endocervical curettage * pregnant * medically unable to undergo surgery

Keywords: cervical dysplasia
efficacy of ain457 in adults (18-65 years) with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: this study is designed as a proof of concept of ain457 in patients with psoriatic arthritis. the study will address the evaluation of the efficacy at 6 and up to 24 weeks after two doses of ain457 10 mg/kg administered three weeks apart.


Eligibility criteria:
inclusion criteria: * a diagnosis of psoriatic arthritis exclusion criteria: * patients with arthritis or ankylosing spondyitis * drug-induced psoriasis * male or female patients who plan to conceive during the time course of the study, or for 6 months after the administration of the second dose. * participation in any clinical trial within 4 weeks prior to initial dosing or longer. * previous use of immunosuppressive agents eg cyclosporine, without the necessary wash-out period * history of severe allergy to food or drugs * positive tb test. other protocol-defined inclusion/exclusion criteria may apply

Keywords: psoriatic arthritis igg1k monoclonal antibody interleukin -17a neutralizing
retention, stability and performance assessment of denture fixatives versus no fixative control

Conditions: Dentures

Summary: this clinical investigation will evaluate the effectiveness, tolerability and safety of two denture fixative creams versus no fixative control

a single-centre, randomised, 3-way cross-over, clinical investigation comparing the performance of two denture fixative versus no denture fixative control in full denture wearers and an exploratory sub study in partial denture wearers. the study will assess the performance and tolerance of two denture fixative cream formulations (paraffin based and polydecene based) when applied to full dentures.

Eligibility criteria:
inclusion criteria: 1. participants with a completely edentulous maxillary \[upper\] arch restored with a conventional full acrylic-based complete denture and dentate, partial, or full edentulous mandibular \[lower\], which may be restored with a stable complete, partial or implant supported denture 2. for complete denture wearers, maxillary \[upper\] dentures must be completely removable standard acrylic dentures, which are at least moderately well-fitting at the screening visit (modified (olshan) kapur index: retention score ≥2, stability score ≥2) 3. male or female participants aged between 18 and 85 years at the time of signing the informed consent form 4. participants must have been using dentures daily for at least 6 months prior to the screening visit 5. dentures must have been made in the last 5 years; 6. dentures must be well-made based on design and construction in the opinion of the clinician 7. no clinically significant and relevant abnormalities in medical history or upon oral examination exclusion criteria: 1. female participants who are pregnant as confirmed by a positive pregnancy test (urine) or are lactating (applicable to female participants of childbearing potential) 2. daily doses of medication that might interfere with the ability to perform the study according to protocol or affect study assessments, for example, bisphosphonates (oral or intravenous) (as determined by the investigator) 3. known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients 4. any clinically significant or relevant oral abnormality (e.g., temporomandibular joint \[tmj\] problems), or recent (within last 6 months) oral surgery / intervention, or oral health concern that, in the opinion of the investigator, could affect the participant's participation in the study 5. participants with maxillofacial defects covered by prosthetics 6. self-reported and/or visual manifestations of severe dry mouth (xerostomia) that may affect denture retention in the opinion of the investigator 7. participants with oral soft tissue examination findings such as stomatitis, open sores, ulcers, lesions, redness or swelling or associated lymphadenopathy

Keywords: denture fixative
the efficacy and safety of paz320 on ppg and insulin blood levels in type ii diabetic patients

Conditions: Type II Diabetes

Summary: the purpose of this study is to test the efficacy of paz320 in diabetic patients.

the purpose of the present clinical study is to test the efficacy of two doses of paz320 in diabetic patients already on treatment with metformin, in order to assess and quantify its effect on postprandial glucose and insulin levels after a standard meal composed of rice, compared to placebo.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with type ii diabetes since at least one year, not presenting any complications of their disease. 2. patients under treatment with metformin up to 3g/day, given twice or three times daily. metformin doses should not exceed 3g/day, and should be well tolerated by the patients, its dose should have been stable for the last 3 months before inclusion in the study. metformin should be taken in the morning of the visit only after the test meal is taken. the next doses of metformin will be taken with meals after the visit, in the habitual order the patient is used to take. the patients should not stop taking metformin during the study, but continue as usual, except that in the mornings of the visits, as the patients arrive in fasting conditions, metformin should be taken after the test meal. if a concomitant combination with an oral anti diabetic agent is given, because of elevated hba1c levels, it should be taken together with metformin after the test meal. 3. age - between 35 and 65, male and female. 4. females should not be pregnant or breast feeding, women of child bearing potential should guarantee anti-contraceptive measures. 5. bmi (body mass index) - between 25 and 32. 6. patients with glycated hemoglobin (hba1c) lower than 9%, and higher than 6.5%, hba1c will be determined in the first visit. 7. patients who are able to collaborate during the entire duration of the study. exclusion criteria: 1. patients with other underlying diseases, such as cardiovascular disease, renal disease, peripheral vascular disease or any condition considered to be a complication of diabetes, should be excluded from this study. 2. patients treated with insulin subcutaneous injections or with glp-1 agonists, or by alpha-glucosidase inhibitors or by glinides should not be included in the study. 3. hba1c higher than 9%, or lower than 6.5% 4. women who are either pregnant or lactating 5. participation in another clinical study in the month preceding recruitment into the study. 6. patients who cannot guarantee compliance.

Keywords: paz320 type ii diabetes metformin galactomannan
the effectiveness of a novel software program to help in rotem interpretation

Conditions: Coagulation Disorder, Blood

Summary: the purpose of this study is to assess a novel rotational thromboelastometry (rotem®) interpretation software to determine whether its use improves the accuracy of clinician interpretation.


Eligibility criteria:
inclusion criteria: * current residents and attending physicians in the university of utah department of anesthesiology who have a range of experience and exposure to thromboelastography exclusion criteria: * refusal to consent or no longer an active member of the university of utah department of anesthesiology
azd0530 phase ii study in patients with advanced ovarian cancer

Conditions: Ovarian Neoplasms; Ovarian Cancer

Summary: the main purpose of this study is to determine if azd0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer


Eligibility criteria:
inclusion criteria: * have a diagnosis of advanced ovarian cancer * have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy * estimated life expectancy of more than 12 weeks exclusion criteria: * central nervous system (cns) metastases * received more than 2 prior chemotherapy regimens for ovarian cancer treatment * inadequate bone marrow reserve * inadequate liver function, renal function or low haemoglobin * pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable method of contraception

Keywords: cancer tumour ovarian neoplasms ovarian cancer
effect of repo in fgf23 in esrd patients

Conditions: Anemia; Chronic Kidney Diseases

Summary: objective: to evaluate the effects of recombinant erythropoietin (repo) in plasma levels of fibroblast growth factor 23 (fgf23) in end-stage renal disease (esrd) patients in hemodialysis. method: prospective cohort of esrd patients in hd, where patients with or without repo therapy were compared. measurements of plasma fgf23 were performed at baseline and during the complete study. demographic, clinical and laboratory data will be obtained. follow-up period: 12 weeks.

experimental data has shown that recombinant erythropoietin (repo) increases plasma levels of fibroblast growth factor 23 (fgf23) in murines, both health and with acute or chronic renal disease. also, observational studies indicate an association between epo and fgf23 levels in patients. until now, it has not been demonstrated whether the use of repo does increase plasma fgf23 in end-stage renal disease (esrd) patients in hemodialysis (a population with a high use of this therapy for the management of chronic anemia). our objective was to evaluate whether the administration of repo increases plasma fgf23 levels in esrd patients in hemodialysis. we performed a prospective cohort with esrd patients without repo therapy. we performed 2 groups: patients with requirements of repo therapy due to anemia (hb \ 10 g/dl). we measured plasma fgf23 (intact and c-terminal) at baseline and during 12 weeks. demographic, clinical and laboratory data was obtained. patients treated with repo received beta-epoetin (recormon, roche), according to current recommendations. patients were follow-up during 3 months to evaluate the effects of repo. our primary outcome was changes in plasma intact fgf23 at 12 weeks, between both groups.

Eligibility criteria:
inclusion criteria: * end-stage renal disease * requirements of hemodialysis * at least 6 months since initiation of hemodialysis exclusion criteria: * pregnancy * treatment with rhepo or analogs during the previous 6 months or earlier
effectiveness of functional electrical stimulation versus spencer technique in patients with adhesive capsulitis

Conditions: Adhesive Capsulitis

Summary: this study focus on the rehabilitation of patients with frozen shoulder through a manual technique called "spencer met".the purpose of this approach is to reduce the pain and improve the rom and quality of life.

by comparing the effectiveness of functional electrical stimulation versus the spencer technique in patients with adhesive capsuilitis is to determine which treatment approach will yields better outcomes in order to reduce the detrimental effects of disease process.spencer mets consist of series of seven steps taken in order to decrease pain and stiffness in sholder regiegionn.

Eligibility criteria:
inclusion criteria: * patients with diabetic frozen shoulder * patients having frozen shoulder after stroke * subjects having stiff shoulder for at least 3 months * subjects with bilateral/unilateral frozen shoulder * subjects with idiopathic frozen shoulder exclusion criteria: * bone fracture within past 12 weeks * patients with hyper mobile joints * subjects with rotator cuff pathology * dislocated shoulder * subjects who had shoulder arthroplasty
effects of aliskiren in elderly hypertensive chronic kidney disease (ckd) patients

Conditions: Hypertension; Chronic Kidney Disease

Summary: the purpose of this study is to determine whether aliskiren is effective in the treatment of blood pressure, hear function, renal function in elderly hypertensive chronic kidney disease (ckd) patients.

chronic kidney disease (ckd) was reported to be affecting 11% of the all population. this number is much higher in the elderly population and may be as high as 30%. ckd is an independent risk factor of cardiovascular disease (cvd). this is called "cardio-renal continuum". the renin-angiotensin-aldosterone system (ras) plays pivotal roles in both cardiovascular and renal functions. the increased oxidative stress by activated ras on vascular endothelium is one of important factor to development of cardio-renal continuum. the blockade of ras by angiotensin i converting enzyme inhibitors (aceis) and/or angiotensin receptor blockers (arbs) has been reported to ameliorate the renal disease and cvd; however,they do not completely suppress ras, leading to a reactive rise in plasma renin activity (pra). aliskiren, an oral direct renin inhibitor, is effective against essential hypertension by reducing pra, resulting in more complete suppression of ras; however, little is known about the effects of aliskiren on heart and kidney functions in elderly hypertensive ckd patients. in this study, we assessed the efficacy of aliskiren on heart and kidney functions in elderly hypertensive ckd patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic kidney disease * clinical diagnosis of hypertension (blood pressure \>=140/90mmhg) * elderly people(\>=65 years old) exclusion criteria: * the patients who are already taking aliskiren * the patients who are receiving hemodialysis or peritoneal dialysis * the patients who are taking cyclosporin * the patients who have hyperkalemia(\>=5.5meq/ml) * severe heart failure (\>=nyha class iii) * insulin dependent diabetic mellitus or poor controlled insulin independent diabetic mellitus (\>=hba1c 9.0\&) * severe liver dysfunction (five folds increased ast or alt than standard values)

Keywords: elderly chronic kidney disease hypertension aliskiren
a study of maintenance treatment with fluzoparib in gbrca/palb2 mutated pancreatic cancer whose disease has not progressed on first line platinum-based chemotherapy

Conditions: Metastatic Pancreatic Cancer

Summary: the study is being conducted to evaluate the tolerability, safety and efficacy of maintenance fluzoparib monotherapy in patients with gbrca/palb2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.


Eligibility criteria:
key inclusion criteria: * aged ≥ 18 years. * eastern cooperative oncology group (ecog) performance status (ps) of 0 or 1 * expected survival ≥ 3 months. * histologically or cytologically confirmed metastatic pancreas adenocarcinoma. * patients who have received a minimum of 16 weeks of continuous platinum treatment for metastatic disease and have no evidence of progression based on investigator's opinion. * patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by ct or mri. * documented mutation in germline brca1/2 or palb2 that is predicted to be deleterious or suspected deleterious. * adequate organ performance based on laboratory blood tests. * women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. * ability to understand and the willingness to sign a written informed consent document. major exclusion criteria: * previous treatment with a poly adp-ribose polymerase (parp) inhibitor. * patients who have had radiotherapy within 2 weeks or participated in another clinical trial with any investigational agents within 2 weeks prior to study screening. * previous treatment using cyp3a4 inducers within 3 weeks or inhibitors within 2 weeks. * significant cardiovascular disease such as new york heart associate class iii/iv, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ecg within 6 months prior to enrolment. * patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication. * patients with myelodysplastic syndrome/acute myeloid leukaemia. * known active hepatitis b or c infection. * history of immunodeficiency (including hiv infection) or organ transplantation. * other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.
management of molar incisor hypomineralization with silver diamine fluoride or smart

Conditions: Dental Caries; Molar Incisor Hypomineralization

Summary: the purpose of this study is to evaluate and compare the clinical performance of silver diamine fluoride+potassium iodide (sdf+ki) and silver-modified atraumatic restorative technique (smart/sdf+ki+gic) on molars with mih

sdf+ki and smart (sdf+ki+gic) were placed on two permanent molar teeth with mih, in a split mouth design. 48 patients were included in the study. the teeth were randomized into two groups according to the dental restorative material. group 1: sdf+ki (riva star), group 2: sdf+ki (riva star) +gic (equia forte). the us public health service criteria (secondary caries, anatomical form, marginal adaptation, marginal discoloration) was used for clinical evaluation of atraumatic resin restorations. the restorations were evaluated at baseline and 1., 6., 12., 18., 24. months. intra-oral photos were taken directly after treatment and at control appointments to evaluate discoloration and seconder caries under magnification. fisher's exact test, kaplan-meier survival curves, log-rank test, mann whitney u test, and friedman test was performed for the statistical analysis.

Eligibility criteria:
inclusion criteria: * patients and parents of the patients who accept to participate and sign the informed consent * patients whose molar teeth are diagnosed as molar incisor hypomineralization by eapd * teeth that are fully erupted * patients who have at least two permanent first molars that need fissure sealant * teeth that have white-yellow-brown discoloration that indicate high-caries risk exclusion criteria: * teeth that are previously restored or have caries * patients who have orthodontic treatment * patients who are not cooperative for the dental procedure * teeth that have dental fluorosis or enamel malformation according to the specific syndromes

Keywords: molar incisor hypomineralization silver diamine fluoride
study of ym155 in refractory diffuse large b-cell lymphoma (dlbcl) subjects

Conditions: Lymphoma, Large-Cell, Diffuse; Lymphoma, B-Cell Refractory

Summary: a study in subjects with a type of b cell lymphoma (dlbcl)to evaluate the response rate, efficacy, safety and tolerability of ym155

1 arm (active), phase 2 study to evaluate response rate, efficacy, safety and tolerability of ym155

Eligibility criteria:
inclusion criteria: * male or female subjects aged 18 years or older * histologically confirmed primary dlbcl of any stage * refractory to the last treatment regimen * previously treated with the following treatment regimens: * anthracycline-based combination chemotherapy with rituximab * second-line combination chemotherapy * autologous bmt if the subject was eligible and did not refuse the procedure * at least one measurable lesion defined as \> 1.5 cm in the longest diameter * no known central nervous system involvement * ecog performance status \< 2 * life expectancy \> 12 weeks * if female, non-pregnant and non-lactating * irb-approved consent and hipaa authorization exclusion criteria: * transformed, composite or discordant lymphoma * therapy for lymphoma within 21 days prior to the first dose of ym155 * within 4 weeks of the screening fdg-pet scan, receipt of the following: * radiation therapy * surgical procedures (except biopsies and central catheter / port placement) * active infection (bloodstream or deep tissue) * inadequate marrow, hepatic and/or renal function * serum creatinine \> 1.5 x uln or calculated serum creatinine clearance \< 60 ml/min * absolute neutrophil count (anc) \< 750/mm3 * platelet \< 50,000/mm3 * alanine transaminase (alt) and aspartate transaminase (ast) \> 2.5 x uln; \> 5 x uln if secondary to liver metastases * treated with \> 3 prior treatment regimens. the following should be considered: * planned maintenance therapy should be considered as part of the previous treatment regimen * any preparative treatment (salvage chemotherapy, high-dose chemotherapy, radiation therapy, etc.) should be included with the autologous bmt or pbsct as one treatment * prior allogeneic bmt or pbsct * previously treated with ym155 * other investigational therapy or procedures within 28 days * known hiv, hepatitis b surface antigen, or hepatitis c antibody * other malignancy requiring treatment within 2 years * significant and/or uncontrolled cardiac, renal, hepatic, or other systemic disorders or significant psychological conditions that in the investigator's judgment would jeopardize subject enrollment or compliance

Keywords: lymphoma, large-cell, diffuse lymphoma, b-cell ym155 treatment outcomes refractory